Company ProfilePremium

Anupam Rasayan India Limited

Company Profile Analysis

Tickers: ANURAS.NS, 543275.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Anupam Rasayan India Limited - Company showcase

Year Founded & Workforce

1984

Anupam Rasayan India Limited logo

Anupam Rasayan India Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Anupam Rasayan India Limited Overview

Anupam Rasayan is a Surat-headquartered custom synthesis and manufacturing (CSM) and specialty chemicals company that has spent the past five years converting itself from a predominantly agrochemical-intermediates supplier into a multi-chemistry, multi-geography CDMO platform. Its historic core is multi-step synthesis for global innovator agrochemical, personal-care and pharmaceutical companies from six plants in Gujarat (~30,000 MT installed capacity). Through three acquisitions it has added backward integration into fluorine (Tanfac Industries, 2022), a US manufacturing base serving electronics, resins and defence-adjacent performance materials (Jayhawk Fine Chemicals, Kansas, closed February 2026), and forward integration into finished pharmaceutical dosage forms (Bliss GVS Pharma, control acquired September 2026). Management frames the combined group as a ~INR 4,000 Cr pro forma revenue platform. The investment case rests on contracted LOI/order-book visibility, fluorination and flow-chemistry know-how, and operating leverage on under-utilised acquired assets; the principal offsets are rising leverage, margin dilution, and a rich valuation.


Company's own description. In its exchange press releases (e.g., FY2026 results release of 23 May 2026 and Q1 FY27 release of 14 August 2026) the company describes itself as one of the leading Indian companies engaged in custom synthesis and manufacturing of specialty chemicals, offering multi-step synthesis and complex chemical reaction technologies to a diverse base of Indian and global customers, operating two business verticals: (i) life-science-related specialty chemicals (agrochemicals, personal care, pharmaceuticals) and (ii) other specialty chemicals / performance materials (specialty pigments and dyes, polymer additives, electronics, EV and battery chemicals, polymers). Management's stated ambition, reiterated in Q4 FY26 and Q1 FY27 commentary, is to build a "globally integrated specialty chemicals and CDMO platform."

Business model. The core model is contract/custom manufacturing: an innovator customer (typically a multinational) transfers or co-develops a molecule (usually an advanced intermediate or active ingredient precursor), Anupam develops and scales the process, and supplies under multi-year purchase agreements or letters of intent (LOIs). Revenue is overwhelmingly product sales (manufactured chemicals sold per kilogram/tonne); there is no material subscription or licensing revenue. Following the Bliss GVS acquisition, a branded-generic formulations business (150+ brands, per acquisition announcement) adds a new revenue type — branded product sales into emerging markets (Africa, Asia, Latin America) and regulated-market supply.

Revenue-model mix (independent characterisation).

Pro forma split per the company's Bliss completion release (29 Sep 2026): standalone INR 1,676 Cr, Tanfac INR 711 Cr, Jayhawk INR 722 Cr, Bliss GVS INR 927 Cr (total ≈ INR 4,036 Cr).

Value-chain position. Anupam sits in the "N-1 / N-2" position: it manufactures advanced intermediates one or two steps before the final active ingredient, plus some actives. Tanfac moves it upstream into basic fluorine (hydrofluoric acid, potassium fluoride, aluminium fluoride), securing key fluorination inputs. Bliss moves it downstream into finished dosage forms (suppositories, pessaries, tablets, capsules, injectables). Jayhawk adds a US-located N-1 capability for epoxy/polyimide/hybrid-resin additives, electronics and semiconductor materials.

Customer types. Global innovator agrochemical companies; Japanese, Korean and European chemical and electronics multinationals (polymer intermediates, liquid-crystal intermediates, engineering fluids, semiconductor/data-centre materials); personal-care ingredient majors; pharmaceutical innovators and generics (KSMs, intermediates, and via Bliss, distributors and governments in emerging markets); battery developers (BasqueVolt LOI). In April 2024 the company stated it served over 73 domestic and international customers including 29 multinationals (company press release, 2 April 2024). Named customers are generally not disclosed due to confidentiality; LOI counterparties are typically described only as "a leading Japanese multinational" etc.

End-markets. Crop protection (55% of standalone FY26 revenue, down from 76% in FY22); pharmaceuticals; personal care; performance materials (polymers/high-performance thermoplastics for aerospace, semiconductor process materials, electronics, liquid crystals, engineering fluids, refrigerants via Tanfac's HFC-32 project); EV / solid-state battery materials; defence and aviation (Jayhawk).

Strategy

Stated strategy (paraphrased themes from FY2026 annual report, results releases and calls).

  1. Build a globally integrated specialty chemicals and CDMO platform spanning KSMs to finished dosage forms.

  2. Diversify away from agrochemicals (76% of standalone revenue in FY2022 → 55% in FY2026) towards pharma, performance materials, electronics, semiconductors, EV/battery and aerospace/defence chemistries.

  3. Deepen fluorination chemistry, anchored by Tanfac backward integration and the ETFA flow platform.

  4. Win long-term, contract-backed volume via LOIs/MPAs with Japanese, Korean and European multinationals; LOI/contract pipeline totals ~INR 17,496 Cr (Q1 FY27 presentation) and order book stood at INR 14,646 Cr at FY2026.

  5. Use acquisitions of under-utilised assets (Jayhawk <10% land use; Bliss ~30% capacity utilisation) to create operating leverage and cross-selling.

  6. Fund growth with structured minority equity and debt to limit parent-level equity dilution.

Initiatives in last 24 months.

Medium-term targets / guidance.

No margin, ROCE or leverage targets were verifiably published.

Products & Services

As a CSM business, Anupam does not publish a molecule-level catalogue; customer confidentiality covers most products. The company reports 125+ commercialised products after adding three in Q1 FY27 (Q1 FY27 investor presentation) and a development pipeline of 90+ molecules (FY2026 presentation, per FilingReader). Below is the most granular public catalogue available.

ARIL standalone — Life sciences

Product lineDescription / capabilitiesTarget customerYear / statusPricing
Agrochemical advanced intermediates & activesMulti-step synthesis of intermediates for insecticides, herbicides, fungicides; capabilities across fluorination, nitration, chlorination, hydrogenation and other complex reactions (company "complex chemical reactions" positioning)Global innovator crop-protection MNCsCore since 1984; 55% of FY26 standalone revenueLong-term contract / LOI pricing; not disclosed
Pharmaceutical intermediates & KSMsKey starting materials and intermediates; fluorinated building blocksPharma innovators / generics; now captive into Bliss formulationsGrowing; management expects pharma to outgrow agro—
Personal-care ingredientsSpecialty molecules for personal care (e.g., cosmetic actives / UV-related chemistries — specific molecules not disclosed)Personal-care ingredient majorsEstablished vertical—

ARIL standalone — Performance materials / other specialty chemicals

Product / programmeDescriptionCounterpartyDateContract value
Polymer & liquid-crystal intermediates (3 molecules)Advanced intermediates for highly specialised polymers and liquid crystals; Anupam exclusive supplier out of IndiaLeading Japanese multinationalEarly 2023~$182m (INR 1,500 Cr) over 7 years
New-age polymer intermediateIntermediate for thermoplastic polymers used in aerospace structural materials, semiconductor process materials, E&E devices, industrial machinery; fully backward-integratedLeading Japanese chemical company25 Dec 2023 (supply from CY2024)$61m (INR 507 Cr) over 9 years
Engineering-fluids moleculesMolecules for engineering fluidsLarge Japanese multinational2 Apr 2024~$90m (INR 743 Cr) over 7 years
Semiconductor / data-centre niche moleculesMultiple niche molecules under a long-term Master Purchase AgreementJapan-based multinational conglomerate12 Jun 2025—
Korean MNC programme10-year LOI (molecule not disclosed)Korean multinational—INR 922 Cr over 10 years (IIFL headline)
Battery specialty chemicalSpecialty chemical for solid-state lithium-metal batteries; subject to product developmentBASQUEVOLT, S.A. (Miñano, Spain)15 Jul 2026Up to $300m cumulative over up to 10 years (non-binding)
Specialty pigments & dyes, polymer additivesLegacy "other specialty chemicals" linesIndustrial customersEstablished—

Flagship technology product — ETFA

AttributeDetail
ProductEthyl trifluoroacetate (ETFA), a fluorinated building block and reagent used to make organic fluorine compounds across pharma, agro and performance materials
TechnologyProprietary "process-by-design" continuous flow chemistry platform; company claims world-first commercial-scale flow production
LaunchCommercialised June 2026 (press release 11 Jun 2026)
Addressable market~$500–600m globally (company estimate)
Claimed advantagesSafety, reproducibility, scalability, efficiency, lower environmental footprint vs batch

Tanfac Industries (fluorochemicals & inorganics, Cuddalore)

ProductUse
Anhydrous / aqueous hydrofluoric acidFeedstock for fluorination; refrigerants; captive to ARIL
Aluminium fluorideAluminium smelting flux
Sodium silicofluorideWater fluoridation, glass, enamels
Potassium fluorideFluorinating agent (key ARIL input — backward integration rationale)
Sulphuric acid and oleumIndustrial acids; captive and merchant
HFC-32 (R-32 refrigerant) — projectCommercialisation targeted Q3 FY27 (management, Q1 FY27 call)
Fluorine derivatives for agro, pharma, polymersValue-added derivatives planned since 2022 acquisition

Tanfac was incorporated 20 December 1972, began commercial production March 1985, and reported FY2026 turnover of INR 711.1 Cr and net worth of INR 373.2 Cr (ARIL Reg. 30 disclosure, 7 Sep 2026). Its single 60-acre site adjoins Cuddalore Port.

Jayhawk Fine Chemicals (USA)

Product lineDescription
Epoxy, polyimide and hybrid-resin additives / curing agentsHigh-performance resins for electronics, energy and infrastructure (CABB description)
Advanced intermediates and active ingredientsCustom manufacturing for regulated-market customers
High-performance materialsSemiconductor, electronics, aviation, defence-adjacent applications (ARIL release)

Jayhawk was founded in 1941; it reported ~$78m revenue and ~$15m EBITDA in calendar 2024 (CABB/ARIL), and has an ~800-acre site with below 10% land utilisation (management, Q1 FY27).

Bliss GVS Pharma (formulations, from 28 Sep 2026)

Product lineDescription
Suppositories & pessariesCore franchise; described as India's first EU-GMP-certified suppository manufacturer; women's-health strength
Tablets, capsules, injectablesFinished dosage forms
Therapeutic coverage150+ brands across anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, anti-diabetic, cardiovascular
CapacityPlants running at ~30% utilisation; management targets 60–70% in 2–3 years

Financial Narrative

Margins (computed from table 6.1)

Revenue CAGR FY2022–FY2026: 21.8% (INR 10,738M → INR 23,655M). FY2023–FY2026 CAGR: 13.9%.

Commentary. The five-year record has three phases. FY2022–FY2023 expansion: post-IPO capacity additions and the Tanfac consolidation drove revenue up 49% in FY2023, but gross margin fell ten points as Tanfac's lower-value inorganic fluorides entered the mix. FY2024–FY2025 agro destocking: global crop-protection channel destocking cut revenue in two consecutive years (−7.9% and −2.6%); Q2 FY25 revenue fell 25% YoY. Operating margins held around 20–21% but rising interest (INR 489M → INR 1,014M) compressed net income to INR 933M in FY2025. FY2026 inflection: revenue jumped 65% on agro recovery, new molecule commercialisation (3 new products), full-year contribution of electronics/polymer LOIs and one month of Jayhawk. However, gross margin fell to 44% (consolidated gross margin declined from 61% to 43% between 9M FY25 and 9M FY26 per company data) and EBITDA margin from 28% to 23%, reflecting mix (lower-margin volume products, Tanfac, Jayhawk at ~19% EBITDA margin) and raw-material pass-through. Q4 FY26 EBITDA margin fell to 22% from 30% YoY. Profit growth (+39% consolidated PAT) lagged revenue growth, and interest cost rose a further 47% to INR 1,487M.

Quarterly trajectory: notes and sources

Notes: Q2 FY26 operating revenue and Q3 FY26 EBITDA/PAT are derived by subtraction from reported 9M and FY totals (9M FY26 EBITDA INR 4,024M; 9M PAT INR 1,660M; FY26 totals), and reconcile to reported annual figures within rounding. Q2 FY26 revenue was reported as INR 731.3 Cr (+148% YoY) with EBITDA margin of 18.6% (Motilal Oswal). Q1 FY27 EBITDA excluding other income was ~INR 1,620M (24.8% margin) versus 26.2% including other income — both figures appear in coverage; the difference is other income. Q1 FY27 PAT attributable to owners was INR 386.4M; depreciation rose to INR 561M from INR 307M, driven by Jayhawk and new assets.

Balance sheet

Goodwill & intangibles: not separately verified; FY2026 total assets rose by INR 27.4bn, largely from the Jayhawk consolidation (~$150m purchase price), implying material goodwill/intangible recognition — check FY2026 annual report Note on business combinations. FY2026 classification shows almost all debt as current (INR 13,038M current portion), which likely reflects working-capital facilities and acquisition bridge borrowings reclassified; refinancing is a monitorable.

Important off-balance-sheet-style feature: Both the Jayhawk ($109m Class B non-voting shares in Doriath, funded largely by an Oaktree Capital affiliate, Altis XII Pte) and Bliss (non-controlling, non-voting equity instruments for the portion above a INR 300 Cr term loan) were funded with structured minority equity. These instruments sit in non-controlling interest rather than debt, so reported debt/equity understates economic leverage; their return terms (preferred return, exit/put rights) are not publicly detailed.

Cash flow

FY2026 OCF was the company's highest ever (FY2026 release). S&P Global data show negative free cash flow per share every year FY2022–FY2026 except FY2023 (INR −31.73, 6.86, −60.66, −40.05, −19.59), i.e., the business has been a persistent consumer of cash due to capex and working capital. No buybacks have been authorised.

Ratios (computed)

ROIC and cash conversion cycle: not publicly disclosed on a consistent basis; standalone inventory rose from INR 863 Cr (FY2022) to INR 1,355 Cr (FY2025) (IIFL data), indicating a structurally long cash cycle typical of CSM (campaign manufacturing and safety stocks for MNC customers).

Trend synthesis. Returns on equity have been in mid-single digits for three years — well below cost of equity — because equity was raised ahead of earnings (IPO 2021, FY2023 raise, 2023–25 preferential issue/warrants) and assets have grown faster than profits. Interest coverage has deteriorated steadily from 10x to 2.6x. The FY2026 improvement in net debt/EBITDA (to 2.8x) is flattered by the reclassification of acquisition funding into minority equity. The equity story depends on Jayhawk/Bliss utilisation gains lifting asset turns from ~0.3x.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRelationshipFunction

Anupam Rasayan India Ltd

India

Parent

CSM / specialty chemicals, six Gujarat plants

Tanfac Industries Ltd

India (listed, BSE 506854)

Subsidiary (joint sector company with TIDCO; ARIL co-promoter with control)

Fluorochemicals and inorganics, Cuddalore

Anupam Japan GK

Japan

Wholly owned subsidiary

Business development / sales, Japan

Anupam Europe AG

—

Wholly owned subsidiary

Business development, Europe

Anupam USA, LLC

USA

Wholly owned subsidiary

US sales

Anupam General Trading FZE

UAE (JAFZA)

Wholly owned subsidiary

Trading, storage, export distribution

Doriath S.à r.l.

Luxembourg

Subsidiary (ARIL holds voting control; Class B non-voting shares held by Oaktree affiliate)

Acquisition vehicle for Jayhawk

Jayhawk Fine Chemicals Corporation

USA (Galena, Kansas)

100% held by Doriath

Performance materials, electronics, resin additives

Mates Visa Consultancy Pvt Ltd

India

Wholly owned SPV (acquired 16 Jul 2026 for INR 0.01M)

Acquisition vehicle / PAC for Bliss GVS

Bliss GVS Pharma Ltd

India (listed)

Subsidiary from 28 Sep 2026 (ARIL + PAC 50.07%)

Finished dosage formulations

Business Verticals

Vertical (% of standalone revenue)FY2022FY2026

Agrochemicals (%)

7655

Vertical (% of standalone FY2026 revenue)

Source A: earnings-call summary (GuruFocus, 25 May 2026)

Source B: investor presentation summary (Multibagg, 23 May 2026)

Agrochemicals

5555

Pharmaceuticals

207

Performance materials

1820

Personal care

718

Business Verticals (FY2026)

Vertical (INR Mn, derived)FY2026

Agrochemicals

9,216

Pharmaceuticals

3,351

Performance materials

3,016

Personal care

1,173

Group Entities — ARIL standalone

Entity (INR Cr, pro forma annual)Pro forma

ARIL standalone

1,676

Bliss GVS Pharma

927

Jayhawk Fine Chemicals

722

Tanfac Industries

711

Total

4,036

Results by Segment

MetricFY2025FY2026

Standalone operating revenue (INR Mn)

8,95916,756

Standalone total income (INR Mn)

9,09216,955

Standalone PAT (INR Mn)

7271,614

Consolidated operating revenue (INR Mn)

14,37023,655

Consolidated PAT incl. minorities (INR Mn)

1,6002,222

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating revenue (INR Mn)

10,73816,01914,75114,37023,655

Revenue growth YoY (%)

31.649.2-7.9-2.664.6

Cost of revenue (INR Mn)

3,7217,1666,2906,20313,233

Gross profit (INR Mn)

7,0168,8538,4618,16610,422

SG&A (INR Mn)

486690754744866

Operating income (INR Mn)

2,4483,6053,0162,9943,849

Interest expense (INR Mn)

2424897931,0141,487

Net income attributable to owners (INR Mn)

1,5221,8081,2869331,701

Dividend per share (INR)

1.502.501.250.751.50

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (FY2025–FY2026)

Metric (company-reported, INR Mn)FY2025FY2026

Total income incl. other income (INR Mn)

14,48523,836

EBITDA incl. other income (INR Mn)

4,1235,430

EBITDA margin (%)

28.522.8

Consolidated PAT incl. NCI (INR Mn)

1,6002,222

PAT margin (%)

11.09.3

Basic & diluted EPS (INR)

—15.09

Operating cash flow (INR Mn)

—3,343

Capex (INR Mn)

—3,150

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (%)

65.355.357.456.844.1

Operating margin (%)

22.822.520.420.816.3

Net margin, owners (%)

14.211.38.76.57.2

Income Statement

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Operating revenue (INR Mn)

4,8587,3155,1246,3586,550

EBITDA incl. other income (INR Mn)

1,2921,3571,3751,4071,749

Consolidated PAT incl. NCI (INR Mn)

485440735560512

Balance Sheet and Share Count (M)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Mn)

28,90537,77946,01752,68980,126

Cash & equivalents (INR Mn)

4231,8782,4981,1303,936

Cash & short-term investments (INR Mn)

4546,2453,4981,2824,106

Short-term debt (INR Mn)

2,0812,3576,98210,2900

Current portion of LT debt (INR Mn)

9331,9681,2341,17613,038

Long-term debt (INR Mn)

4,9453,5501,9711,7125,108

Total debt (INR Mn)

8,3628,21710,69114,26119,129

Net debt (INR Mn)

7,9081,9727,19212,97815,023

Total common equity (INR Mn)

17,26923,72627,61028,50333,338

Total current assets (INR Mn)

14,46621,11222,26625,73037,275

Total current liabilities (INR Mn)

5,9518,10813,16218,08226,154

Working capital (INR Mn)

8,51513,0049,1047,64811,121

Shares outstanding (M)

100.25107.46109.79109.93113.73

Cash Flow and Per-Share Data

Metric (INR Mn)FY2025FY2026

Operating cash flow (INR Mn)

—3,343

Capex (INR Mn)

—3,150

Free cash flow, OCF − capex (INR Mn)

—193

Dividends declared per share (INR)

0.751.50

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, owners NI / closing equity (%)

8.87.64.73.35.1

ROA, owners NI / total assets (%)

5.34.82.81.82.1

Current ratio (x)

2.432.601.691.421.43

Debt / equity (x)

0.480.350.390.500.57

Interest coverage, EBIT / interest (x)

10.17.43.83.02.6

Asset turnover (x)

0.370.420.320.270.30

Financial Ratios (x)

RatioFY2025FY2026

Net debt / EBITDA (x)

3.152.77

Geography Metric Details

Geography metricQ1FY27

Export share of consolidated revenue (%)

36

Share Price & Returns

Reference pointPrice (INR)Return to ₹1,170.50 (16 Oct 2026)

IPO price (Mar 2021)

555+111%

~18 Oct 2025

1,061.05+10.3%

3-year (as of Sep 2026, Anand Rathi)

—

~+24.6%

52-week high / low

1415.40 / 1047.40

−17.3% / +11.8%

Market Valuation

Metric20212022202320242025

Year-end market cap (INR Bn)

99.0072.84115.2279.39150.15

Valuation Multiples

MultipleAnupam RasayanSource / note

P/E (TTM)

~81x

IIFL (80.9x), Kotak (81.4x)

P/E FY2027E

~41x

MarketScreener consensus

P/B

~4.1x

IIFL (book value ₹286.95)

EV/Sales FY2026

~6x (approx.; EV ~INR 147bn / sales INR 23.7bn)

Derived; EV excludes minority-equity instruments

EV/EBITDA FY2026

~36x

Trendlyne (36.2x)

Specialty-chem peer P/E

~30x FY28E

Deven Choksey

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

1.502.501.250.751.50

Credit Ratings

AgencyInstrumentRatingOutlookDate

CRISIL

Long-term bank facilities / NCDs

A+

Rating Watch with Developing Implications

Placed 4 Jun 2026; continued 31 Aug 2026

CRISIL

Short-term facilities

A1

Watch Developing

Same

Moody's / S&P / Fitch

—

Not rated

——

Analyst Conclusions

Management guidance (Q1 FY27 call, 14 Aug 2026). FY27 consolidated revenue growth above 30% (organic 20–25% plus 10–15 pp from Jayhawk), excluding Bliss (consolidated from late September 2026, which adds a further increment to H2 FY27). Tanfac HFC-32 commercialisation in Q3 FY27. Bliss utilisation to double over 2–3 years. No explicit margin guidance.

Consensus expectations. FY27E revenue ~INR 34.6bn and FY28E ~INR 45.8bn (Deven Choksey); FY27E P/E ~41x implies roughly doubling EPS from FY2026's ₹15.09.

Bull case.

  1. Operating leverage on acquired assets: Jayhawk (<10% site utilisation, ~19–20% EBITDA margin) and Bliss (30% utilisation) can grow with modest capex, lifting asset turns from ~0.30x and ROE from ~5% toward double digits.

  2. Contracted pipeline conversion: ~INR 17,500 Cr of LOIs/contracts — about 7x FY2026 revenue — skewed to electronics, polymers and battery materials with higher structural growth than agro.

  3. Technology moat in fluorine: integrated HF→KF→ETFA→fluoropolymer intermediates plus first-mover flow chemistry in a $500–600m ETFA market.

Bear case.

  1. Earnings quality and leverage: PAT grew 6% in Q1 FY27 on 36% revenue growth; interest coverage is 2.6x; FCF has been negative in four of five years; CRISIL watch persists.

  2. Hidden cost of structured equity: Oaktree-funded Class B shares ($109m at Doriath) and Bliss non-voting instruments shift economics to minorities — consolidated PAT of INR 2,222M vs owners' INR 1,701M in FY2026 already shows ~23% leakage.

  3. Valuation: ~81x trailing P/E and ~36x EV/EBITDA versus specialty-chem peers at ~30x forward P/E leave little margin for integration slippage or agro relapse.

Catalysts & monitorables (next 12 months).

  • Q2 FY27 results (expected late Oct/Nov 2026; trading window closed 1 Oct) — first full Jayhawk quarter, margin trajectory.

  • First Bliss consolidation (Q3 FY27) and any segment re-definition.

  • CRISIL resolution of Watch Developing.

  • Tanfac HFC-32 start-up (Q3 FY27).

  • ETFA customer qualifications and volumes; additional flow-chemistry molecules.

  • Conversion of BasqueVolt LOI to definitive supply agreement.

  • Promoter pledge levels; disclosure of minority-equity terms.

  • Refinancing of current debt; working-capital release.

  • Q4 FY27 delivery against >30% growth guidance.

Analyst verdict. Anupam Rasayan has executed one of the most aggressive transformations among Indian mid-cap specialty chemical companies. In under five years it has moved from a Gujarat-based, agro-heavy custom synthesiser to a four-pillar group — standalone CSM, Tanfac fluorochemicals, Jayhawk US performance materials and Bliss GVS formulations — with pro forma revenue near INR 4,000 Cr, roughly 1.7x FY2026 reported revenue. The strategic logic is coherent: fluorine integration and flow chemistry provide technical differentiation; Japanese electronics and polymer contracts diversify end-markets; and buying under-utilised assets creates operating leverage that greenfield capex could not deliver as quickly.

The financial evidence, however, has not yet caught up with the narrative. Margins have compressed (EBITDA from 28% to 23% in FY2026), returns on equity remain around 5%, interest coverage has fallen to 2.6x, and free cash flow has been persistently negative. The heavy use of structured minority equity keeps headline leverage manageable but diverts a growing share of profits away from ordinary shareholders and obscures the true cost of capital. CRISIL's continued watch status is a reasonable reflection of that uncertainty.

At ~81x trailing and ~41x forward earnings, the market is already discounting successful integration and pipeline conversion. The next three to four quarters are therefore decisive: investors should look for (i) consolidated EBITDA margins stabilising at or above the mid-20s with Bliss included, (ii) PAT growth converging with revenue growth as depreciation and interest normalise, (iii) clear disclosure of the economics of the Oaktree and Bliss instruments, and (iv) deleveraging or credit-watch resolution. Our synthesis: strategically well-positioned and operationally improving, but priced for execution.


Principal sources: NSE/BSE filings and press releases of Anupam Rasayan India Ltd (FY2025–Q1 FY27); FY2025-26 Integrated Annual Report (submission notice, Sep 2026); CRISIL rating rationales (Mar, Jun, Aug 2026); CABB Group press release (26 Feb 2026); Bliss GVS Pharma SAST disclosures (Sep 2026); S&P Global Market Intelligence data via StockAnalysis.com; Value Research, Upstox, Anand Rathi, IIFL, MarketScreener, Sustainalytics; Deven Choksey Research via DSIJ (Aug 2026); Business Standard, Reuters, Outlook Business, Indian Chemical News, Chemical Weekly, Multibagg, FilingReader, Investywise summaries of filings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / contextNotes

Anand Desai

Managing Director

Founder-promoter; leads company since partnership era

Public face of all major transactions

Mona Desai

Vice-Chairperson & Whole-time Director (title per company materials; verify)

Promoter family

—

Gopal Agrawal

Chief Executive Officer

Listed as CEO on Q2 FY26 earnings call (Oct 2025)

—

Amit Khurana

Chief Financial Officer

Listed as CFO on Q2 FY26 call

—

Ravi Desai

Chief Operating Officer

Promoted from Sales Head; COO effective 14 Aug 2026; remains KMP

—

Hetvi Vyas

Deputy CFO & KMP

Effective 8 Sep 2026; CA with 9+ years' experience; joined 2023; managed international subsidiaries and post-acquisition integration

Replaced Vishal Thakkar

Vishal Thakkar

Former Deputy CFO

Resigned effective 23 May 2026

—

Shareholding Trend

Holder category (%)Jul2025Sep2025Dec2025Mar2026Jun2026

Promoters (%)

59.0759.0759.0759.0759.07

FIIs (%)

7.757.637.606.917.52

Mutual funds (%)

1.781.030.090.15—

Other DIIs (%)

0.100.350.330.200.39

Major Shareholders

HolderStakeCategory

Kiran Pallavi Investments LLC

~32.9%

Foreign promoter (MarketsMOJO)

Anand Desai, Mona Desai and Indian promoter group

~26% (residual of 59.07%)

Indian promoters

Foreign portfolio investors (aggregate)

~7–8%

—

Mutual funds

<0.5%

Domestic MF ownership has collapsed from 5.91% (Dec 2022)

Competitive Landscape

Competitors by Segment

SegmentNamed competitors

Indian CSM / agro intermediates

PI Industries, Navin Fluorine (CDMO), Aarti Industries, Tatva Chintan, Neogen Chemicals

Fluorochemicals

SRF Ltd, Navin Fluorine International, Gujarat Fluorochemicals

Specialty / advanced intermediates

Aether Industries, Deepak Nitrite, Clean Science & Technology, Laxmi Organic, Fine Organic Industries

Global CDMO / fine chemicals

Lonza, Siegfried, CABB Group, Saltigo (Lanxess), WuXi STA

US performance materials (Jayhawk)

VanDeMark Chemical and others (CB Insights)

Formulations / suppositories (Bliss)

Not specifically benchmarked; Indian branded-generic exporters to Africa

Peer Comparison FY2026

MetricAnupam RasayanAether IndustriesDeepak NitriteAarti IndustriesFine Organic

Market cap (INR Cr)

13,43922,54820,88217,26515,706

Revenue TTM (INR Cr)

2,5351,2248,5759,0132,472

Net profit TTM (INR Cr)

225235783531442

Net margin (%)

8.7918.799.085.8817.20

Company Snapshot

$273.2M

Revenue

1984

Founded

Surat, India

Headquarters

SWOT Analysis

Strengths

  • Record scale: FY2026 consolidated revenue INR 23,836M (+65%), highest-ever OCF INR 3,343M (FY2026 release).
  • Contracted pipeline: order book INR 14,646 Cr (FY2026) and LOI/contract table totalling ~INR 17,496 Cr (Q1 FY27 presentation).
  • Technology differentiation: world-first commercial ETFA via continuous flow (Jun 2026).
  • Fluorine integration via Tanfac (HF, KF), reducing input-supply risk (2022 acquisition rationale).
  • Diversification progress: agro share down from 76% (FY2022) to 55% (FY2026).
  • Deep Japanese MNC relationships: four disclosed Japanese programmes 2023–2025 worth >$330m disclosed value plus an MPA.
  • Investment-grade credit at CRISIL A+ / A1.

Weaknesses

  • Margin dilution: EBITDA margin fell from 28% (FY2025) to 23% (FY2026); gross margin from 57% to 44%.
  • Weak returns: owners' ROE 3.3–5.1% in FY2025–FY2026.
  • Rising interest burden: interest expense up 6x from INR 242M (FY2022) to INR 1,487M (FY2026); EBIT coverage 2.6x.
  • Negative free cash flow per share in four of five years (S&P data).
  • Profit lag: Q1 FY27 PAT +6% vs revenue +36% due to depreciation (INR 561M vs 307M) and finance costs.
  • Promoter pledge rising to ~19.5% of promoter holding.
  • Collapse of domestic mutual-fund ownership (5.91% Dec 2022 → ~0.15% Mar 2026).

Opportunities

  • Jayhawk utilisation: <10% of ~800-acre site used; management sees 10–15 pp FY27 growth add.
  • Bliss utilisation 30% → 60–70% target in 2–3 years.
  • HFC-32 commercialisation at Tanfac targeted Q3 FY27.
  • BasqueVolt LOI conversion (up to $300m).
  • ETFA $500–600m TAM and extension of flow platform to other fluorinated molecules.
  • Cross-selling KSMs/APIs into Bliss formulations and Jayhawk's US customers.
  • Sell-side forecast FY26–FY28 revenue CAGR of 39% (Deven Choksey, Aug 2026).

Threats

  • Agrochemical cyclicality (FY2024–25 revenue declines).
  • Chinese competition and pricing pressure in intermediates.
  • Integration risk across three acquisitions in 4.5 years, including a new business model (branded formulations).
  • Structured minority equity (Oaktree-backed Class B; Bliss non-voting instruments) carries undisclosed return/exit terms that could transfer value from parent shareholders.
  • Credit watch: CRISIL Watch Developing since June 2026.
  • HFC phase-down regulation (Kigali) over HFC-32's life.
  • Non-binding nature of key LOIs (BasqueVolt explicitly contingent on product development).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23 May 2025FY2025 results (revenue INR 14,370M, −2.6%)Trough year after agro destocking
12 Jun 2025MPA with Japanese multinational conglomerateSemiconductor/data-centre exposure
15 Jul 2025Warrant conversion (3.91m shares at ₹945.11); interim dividendDilution; equity inflow ~INR 277.5Cr balance
13 Aug 2025Q1 FY26 results: revenue INR 4.91bn (+93% YoY)Recovery confirmed
17 Oct 2025Q2 FY26: revenue INR 731 Cr (+148%), PAT INR 44 Cr, EBITDA margin 18.6%Volume surge, margin dilution; stock −3%
9 Dec 2025Board meeting; Jayhawk definitive agreement (Dec 2025)First overseas acquisition
14 Feb 2026Q3 FY26 results; 9M revenue +84%; USD 50m credit facilitiesFunding in place
20 Feb 2026USD 30m ECB executedAcquisition debt
26–27 Feb 2026Jayhawk closing (~$150m)US platform consolidated
27 Feb 2026Promoter pledges 5.0m shares to Tata CapitalGovernance flag
4 Mar 2026Promoter releases pledge on 4.249m sharesPartial reversal
18 Mar 2026CRISIL reaffirms A+/StableCredit comfort post-Jayhawk
Apr 2026Postal ballot: three special resolutions; later resolutions passed with >99.94% supportShareholder approvals
20 May 2026Board to consider INR 160 Cr NCD private placementLeverage increase
23 May 2026FY2026 results (revenue INR 23,836M +65%; PAT INR 2,222M +39%); ₹1.50 dividend; Bliss SPA; Deputy CFO resignsLandmark year; pharma pivot
25 May 2026Q4 FY26 earnings callQ4 margin 22% vs 30%
1 Jun 2026Bliss open offer public announcement (₹299; up to 27.7m shares; INR 829 Cr)Mandatory offer
4 Jun 2026CRISIL places ratings on Watch DevelopingFunding/integration uncertainty
9 Jun 2026Investor meet at Jhagadia plantIR engagement
11 Jun 2026ETFA flow-chemistry commercialisationTechnology milestone
5–6 Jul 2026Tanfac proposes INR 173.5 Cr preferential issue (later cut to INR 99.41 Cr)Subsidiary funding
15 Jul 2026BasqueVolt LOI (up to $300m)Battery chemicals optionality; stock slipped intraday
16 Jul 2026Mates Visa SPV acquiredBliss vehicle
21 Jul 2026Letter of offer dispatched; INR 160 Cr escrowOffer mechanics
28 Jul – 10 Aug 2026Bliss tender period; 1,669 shares tenderedOffer price far below market
14 Aug 2026Q1 FY27: revenue +36%, PAT +6%; Ravi Desai COO; FY27 guidance raised to >30%Growth up, profit flow-through weak
15 Aug 2026Results published (Reg. 47)Compliance
19 Aug 2026Deven Choksey Research result update (rating changed; FY27E revenue INR 34,585M)Sell-side estimates
31 Aug 2026CRISIL continues Watch DevelopingCredit overhang
7 Sep 2026Board: AGM 30 Sep; record date 18 Sep; Tanfac subscription INR 60.88 Cr; Hetvi Vyas Deputy CFOGovernance & capital allocation
Sep 2026FY2025-26 Integrated Annual Report submittedPrimary disclosure
28 Sep 2026Bliss GVS control acquired (50.07% with PAC)Third acquisition complete
30 Sep 202623rd AGM—
1 Oct 2026Trading window closed pending Q2 FY27 resultsQ2 results imminent (date not yet verified)
~12 Oct 2026FY2026 sustainability report with ESG targets filedESG disclosure
14 Oct 2026ESG
By 29 Oct 2026FY2026 final dividend payment due—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Agrochemicals was INR 9,216 Mn in FY2026.
Anupam Rasayan India Limited — Revenue by Segment
Series (INR Mn)FY2026
Agrochemicals9,216
Pharmaceuticals3,351
Performance materials3,016
Personal care1,173

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.